Third Wave Expects Revenue From Molecular Dx to Be Between $23M and $26M in 2005 | GenomeWeb

NEW YORK, Nov. 11 (GenomeWeb News) - Third Wave Technologies expects revenues from clinical molecular diagnostic products to expand to between $23 million and $26 million in 2005, the company said today.

The company said the revenue will be "driven chiefly by the company's core genetics, cystic fibrosis and HCV genotyping reagents."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.